Pain Therapeutics, Durect take a beating over US FDA rejection of Remoxy
This article was originally published in Scrip
Executive Summary
Anguished investors fled from shares of Pain Therapeutics and Durect on 24 June after the US FDA again rejected Remoxy, an investigational extended-release oral formulation of oxycodone intended to provide relief of moderate to severe pain requiring continuous, around-the-clock opioid treatment.